Table: Santen Pharm -Q1 group results (IFRS)

SANTEN PHARMACEUTICAL

01/08/2018 07:00

Aug 1 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2018        Jun 30, 2017     Mar 31, 2019 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               56.48               55.95           237.00    
                   (+1.0 pct)          (+11.9 pct)      (+5.4 pct)  
  Operating           10.02               12.06            40.70    
                   (-16.9 pct)         (+11.5 pct)      (+5.2 pct)  
  Pretax               9.46               12.08            41.30    
                   (-21.7 pct)         (+17.8 pct)      (+5.2 pct)  
  Net                  6.85                9.02                     
                   (-24.0 pct)         (+23.1 pct)                  
  EPS Basic         16.85 yen           22.20 yen        75.21 yen  
  EPS Diluted       16.79 yen           22.12 yen                   
  Ann Div                               26.00 yen        26.00 yen  
  -Q2 Div                               13.00 yen        13.00 yen  
  -Q4 Div                               13.00 yen        13.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T